Exposure to Amlodipine in the First Trimester of Pregnancy and During Breastfeeding

Abstract

Objective: To assess the fetal outcome of three hypertensive women exposed to amlodipine. 5 mg/day, in the first trimester of pregnancy. Case 1: The patient was treated with amlodipine until 7 weeks of gestation. She was also exposed to levosulpiride, aluminum hydroxide gel, magnesium carbonate, and Ginkgo biloba. At 38⁺³ weeks of pregnancy, she delivered a 3750 g healthy female baby, and restarted taking amlodipine, 5 mg/day, while exclusively breastfeeding her daughter. At three months of age, the infant was healthy. Case 2: The patient was treated with amlodipine from 2⁺² to 3⁺⁴ weeks of pregnancy. Her treatment was modified to atenolol until the week 6^{+4 weeks}, when she declined any antihypertensive treatment. At 39⁺⁴ weeks of pregnancy, the patient delivered a 2600 g baby. At 20 months old, the baby presented with intellectual delay and weakness in the left arm and hand grasp. These neurological alterations were not attributed to her exposure to amlodipine early in utero. Case 3: The patient was treated with amlodipine from 7⁺⁶ to 12 weeks of pregnancy. She was also taking sucralfate and lorazepam. At 12 weeks of amenorrhea, ultrasound revealed a 15.3 mm, single fetal pole in the gestational sac without cardiac activity. She underwent dilatation and evacuation of a dead embryo. Conclusion: As reported with other calcium-channel blockers, amlodipine does not appear to be teratogenic and it appears to be compatible with breastfeeding.

Keywords:

• Antihypertensive agents
• Calcium channel blockers
• Maternal-fetal relations